浏览全部资源
扫码关注微信
- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
Preparation of celastrol-loaded albumin nanoparticles and their efficacy against rheumatoid arthritis
- ZHONGGUO YAOFANG Vol. 33, Issue 21, Pages: 2597-2602(2022)
- 作者机构：
贵州中医药大学药学院/国家苗药工程技术研究中心/贵州省中药民族药炮制与制剂工程技术研究中心，贵阳 550025
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2022.21.07
CLC： R943;R965Published：15 November 2022，
Received：22 May 2022，
Revised：22 September 2022，
扫 描 看 全 文
闫汉语,张永萍,徐剑等.雷公藤红素白蛋白纳米粒的制备及抗类风湿性关节炎药效评价 Δ[J].中国药房,2022,33(21):2597-2602.
YAN Hanyu,ZHANG Yongping,XU Jian,et al.Preparation of celastrol-loaded albumin nanoparticles and their efficacy against rheumatoid arthritis[J].ZHONGGUO YAOFANG,2022,33(21):2597-2602.
闫汉语,张永萍,徐剑等.雷公藤红素白蛋白纳米粒的制备及抗类风湿性关节炎药效评价 Δ[J].中国药房,2022,33(21):2597-2602. DOI： 10.6039/j.issn.1001-0408.2022.21.07.
YAN Hanyu,ZHANG Yongping,XU Jian,et al.Preparation of celastrol-loaded albumin nanoparticles and their efficacy against rheumatoid arthritis[J].ZHONGGUO YAOFANG,2022,33(21):2597-2602. DOI： 10.6039/j.issn.1001-0408.2022.21.07.
摘要
目的
2
制备雷公藤红素白蛋白纳米粒（CLT-AN），并考察其体内抗类风湿性关节炎（RA）活性。
方法
2
采用超声法制备CLT-AN，以粒径、分散指数（PDI）和稳定性为评价指标，以CLT投药量、大豆油用量和超声功率为考察因素，通过单因素实验优化处方工艺。利用透射电镜、激光粒度测定仪等考察CLT-AN的理化性质，并研究其体外稳定性和体外释放特性。构建佐剂诱导关节炎大鼠模型，考察CLT-AN对模型大鼠关节肿胀、血清中炎症因子[肿瘤坏死因子α（TNF-α）和白细胞介素1β（IL-1β）]水平以及关节组织病理状态的影响。
结果
2
优化的处方为CLT 6.5 g、大豆油45 mg、超声功率490 W、超声时间8 min。按最佳处方制备的CLT-AN外观形态圆整，平均粒径为（96.8±1.1） nm，PDI为0.174±0.020，Zeta电位为（－18.6±1.7） mV，包封率为（94.61±0.46）%，载药量为（2.42±0.21）%。在室温条件下，CLT-AN储存5 d内的粒径、PDI、Zeta电位和包封率均无显著变化。CLT-AN体外释放缓慢，72 h的累积释放量可达到73.56%；与游离CLT相比，CLT-AN可明显抑制模型大鼠的关节肿胀，降低其血清中TNF-α、IL-1β水平，并且显著改善炎症关节组织的病理状态。
结论
2
超声法制备的CLT-AN粒径适中、稳定性良好，具有显著的缓释特征和优良的抗RA活性。
Abstract
OBJECTIVE
2
To prepare celastrol-loaded albumin nanoparticles （CLT-AN）， and to investigate their activity against rheumatoid arthritis （RA）
in vivo
.
METHODS
2
CLT-AN was prepared by ultrasonic method. The formulation technology was optimized by single-factor test by taking particle size， polydispersity index （PDI） and stability as indexes， with the dosage of CLT， the dosage of soybean oil and the ultrasonic power as factors. The physical and chemical properties of CLT-AN were investigated by transmission electron microscopy （TEM） and laser particle size analyzer；
in vitro
stability and release profile were studied. A rat model of adjuvant-induced arthritis was constructed to investigate the effects of CLT-AN on joint swelling， the levels of serum inflammatory factors [tumor necrosis factor α （TNF-α） and interleukin-1β （IL-1β）] and pathological state of joint tissue.
RESULTS
2
The optimized formulation was CLT 6.5 g， soybean oil 45 mg， ultrasonic power 490 W， ultrasonic time 8 min. CLT-AN prepared by the best formulation showed uniform and spherical morphology. Its particle size， PDI， Zeta potential were （96.8±1.1） nm， 0.174±0.020， and （－18.6±1.7） mV， respectively. The encapsulation efficiency and drug-loading efficiency were （94.61±0.46）% and （2.42±0.21）%. There were no significant changes in particle size， PDI， Zeta potential and encapsulation efficiency of CLT-AN within 5 days of storage at room temperature. CLT-AN was slowly released
in vitro
， and the cumulative release reached 73.56% in 72 h. Compared with CLT， CLT-AN could significantly inhibit the joint swelling of model rats， reduced the levels of inflammatory factors TNF-α and IL-1β in serum， and improved the pathological state of inflammatory joint tissue.
CONCLUSIONS
2
CLT-AN prepared by ultrasonic method has the appropriate particle size， good stability， significant sustained-release characteristics， and excellent therapeutic efficacy against RA.
关键词
雷公藤红素白蛋白纳米粒处方工艺理化性质类风湿性关节炎
Keywords
for- mulation technologyphysicochemical propertiesrheumatoid arthritis
references
MCINNES I B，SCHETT G. Pathogenetic insights from the treatment of rheumatoid arthritis[J]. Lancet，2017，389（10086）：2328-2337.
SALMINEN A，LEHTONEN M，PAIMELA T，et al. Celastrol：molecular targets of thunder god vine[J]. Biochem Biophys Res Commun，2010，394（3）：439-442.
KANNAIYAN R，SHANMUGAM M K，SETHI G. Molecular targets of celastrol derived from Thunder of God Vine：potential role in the treatment of inflammatory disorders and cancer[J]. Cancer Lett，2011，303（1）：9-20.
AN L M，LI Z R，SHI L Q，et al. Inflammation-targeted celastrol nanodrug attenuates collagen-induced arthritis through NF-κB and Notch1 pathways[J]. Nano Lett，2020，20（10）：7728-7736.
VENKATESHA S H，YU H，RAJAIAH R，et al. Celastrus-derived celastrol suppresses autoimmune arthritis by modulating antigen-induced cellular and humoral effector responses[J]. J Biol Chem，2011，286（17）：15138-15146.
YU Y，KOEHN C D，YUE Y，et al. Celastrol inhibits inflammatory stimuli-induced neutrophil extracellular trap formation[J]. Curr Mol Med，2015，15（4）：401-410.
ASTRY B，VENKATESHA S H，LAURENCE A，et al. Celastrol，a Chinese herbal compound，controls autoimmune inflammation by altering the balance of pathogenic and regulatory T cells in the target organ[J]. Clin Immunol，2015，157（2）：228-238.
GAN K，XU L X，FENG X K，et al. Celastrol attenuates bone erosion in collagen-induced arthritis mice and inhi- bits osteoclast differentiation and function in RANKL-induced RAW264.7[J]. Int Immunopharmacol，2015，24（2）：239-246.
XU Z T，WU G S，WEI X，et al. Celastrol induced DNA damage，cell cycle arrest，and apoptosis in human rheumatoid fibroblast-like synovial cells[J]. Am J Chin Med，2013，41（3）：615-628.
GUO L，LUO S，DU Z，et al. Targeted delivery of celastrol to mesangial cells is effective against mesangioproli- ferative glomerulonephritis[J]. Nat Commun，2017，8（1）：878.
WANG Q，JIANG J Y，CHEN W F，et al. Targeted deli- very of low-dose dexamethasone using PCL-PEG micelles for effective treatment of rheumatoid arthritis[J]. J Control Release，2016，230：64-72.
ISHIMA Y，MARUYAMA T. Human serum albumin as carrier in drug delivery systems[J]. Yakugaku Zasshi，2016，136（1）：39-47.
LEVICK J R. Permeability of rheumatoid and normal human synovium to specific plasma proteins[J]. Arthritis Rheum，1981，24（12）：1550-1560.
WUNDER A，MÜLLER-LADNER U，STELZER E H， et al. Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis[J]. J Immunol，2003，170（9）：4793-4801.
HE X Y，XIANG N X，ZHANG J J，et al. Encapsulation of teniposide into albumin nanoparticles with greatly lowered toxicity and enhanced antitumor activity[J]. Int J Pharm，2015，487（1/2）：250-259.
YI X L，LIAN X H，DONG J X，et al. Co-delivery of pirarubicin and paclitaxel by human serum albumin nanoparticles to enhance antitumor effect and reduce systemic toxicity in breast cancers[J]. Mol Pharm，2015，12（11）：4085-4098.
SMOLEN J S，STEINER G. Therapeutic strategies for rheumatoid arthritis[J]. Nat Rev Drug Discov，2003，2（6）：473-488.
WANG Q，SUN X. Recent advances in nanomedicines for the treatment of rheumatoid arthritis[J]. Biomater Sci，2017，5（8）：1407-1420.
PENG X，WANG J，SONG H，et al. Optimized preparation of celastrol-loaded polymeric nanomicelles using rotatable central composite design and response surface methodology[J]. J Biomed Nanotechnol，2012，8（3）：491-499.
ZHANG J，LI C Y，XU M J，et al. Oral bioavailability and gender-related pharmacokinetics of celastrol following administration of pure celastrol and its related tablets in rats[J]. J Ethnopharmacol，2012，144（1）：195-200.
FU Q，SUN J，ZHANG W P，et al. Nanoparticle albumin-bound （NAB） technology is a promising method for anti-cancer drug delivery[J]. Recent Pat Anticancer Drug Discov，2009，4（3）：262-272.
KRATZ F. Albumin as a drug carrier：design of prodrugs，drug conjugates and nanoparticles[J]. J Control Release，2008，132（3）：171-183.
HUANG Y L，ZHOU D，HANG T J，et al. Preparation，characterization，and assessment of the antiglioma effects of liposomal celastrol[J]. Anticancer Drugs，2012，23（5）：515-524.
刘鹏，陈莹. HPLC-超滤法测定雷公藤红素与家兔、大鼠、人血浆的蛋白结合率[J].中国药房，2015，26（1）：62-65.
REN H W，HE Y W，LIANG J M，et al. Role of liposome size，surface charge，and PEGylation on rheumatoid arthritis targeting therapy[J]. ACS Appl Mater Interfaces，2019，11（22）：20304-20315.
0
Views
0
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.